Comment from Jazz Pharmaceuticals

Summary: Jazz Pharmaceuticals supports the modernization of SUPAC guidances to move from a prescriptive framework to a more flexible, risk-based lifecycle management system aligned with ICH Q9 and Q12. They argue for the integration of Post-Approval Change Management Protocols (PACMPs), the use of advanced analytical tools to reduce bioequivalence studies, and greater harmonization with global regulatory frameworks.